OncoMatch/Clinical Trials/NCT05674825
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Is NCT05674825 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Targeted agent and Standard of care agent for cancer.
Treatment: Targeted agent · Standard of care agent — This is a prospective, open-label navigational investigation designed to evaluate the feasibility of using molecular profile-based evidence to determine individualized cancer therapy for patients with aggressive malignancies. This is a non-randomized, histology-agnostic trial. Although there will be a case mix of histologies, the investigators now know that individual histologies are composed of a heterogeneous mix of molecular alterations. It is not clear whether one case mix is better or worse than another. Thus, the investigators are testing a strategy of molecular matching that may apply across different cancers.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L
Kidney function
Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 30 ml/min
Liver function
Total bilirubin ≤ 2.0 x institution's upper limit of normal (ULN); ALT and AST ≤ 3 x institutional ULN (patients without underlying liver disease)
Cardiac function
New York Heart Association (NYHA) Functional Classification I-II
Adequate organ and marrow function as defined below: Absolute neutrophil count ≥ 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Total bilirubin ≤ 2.0 x institution's upper limit of normal (ULN); Patients without underlying liver disease: ALT and AST ≤ 3 x institutional ULN; Serum creatinine ≤ 2.0 x institution's ULN or 24-hour creatinine clearance ≥ 30 ml/min. New York Heart Association (NYHA) Functional Classification I-II
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert Hospital & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify